The abstract is read at the publisher; the summary is JClub's.
A consensus expert framework proposes how to define disease modification in systemic sclerosis by integrating vascular, inflammatory, and fibrotic domains across heterogeneous patients.
- Why it matters: Heterogeneity in systemic sclerosis has blocked a unified, practical definition of disease modification, limiting how trials and drug development can demonstrate meaningful long-term benefit.
- What they did: The authors used a consensus approach among systemic sclerosis experts to outline challenges and specify that disease-modifying treatments should target core pathways or cells and show sustained effects.
- The result: The framework supports preclinical modeling and clinical trial design aimed at demonstrating sustained disease activity control and prevention of progression of damage across organs, manifestations, stages, and endotypes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.